Xencor (United States)

Recent papers from Xencor (United States)

1. AFM Force-to-Signal Assay Uncovers Glypican-1 and TRP Channel Roles in Endothelial MechanotransductionAJP Heart and Circulatory Physiology · 2026
2. A blinded, prospective benchmark of in silico antibody discovery anchored to experimental affinity and developabilityNature Biotechnology · 2026
3. CD2 x IL2RG bispecific antibodies synergistically modulate lymphocyte activation, resulting in suppression of inflammation and prevention of GVHD 2258985The Journal of Immunology · 2026
4. Severe hypoxia drives loss of ST6GAL1-mediated α2,6-sialylation in the epicardial secretome impairing angiogenic activity.2026
5. Abstract 2640: XmAb808, a B7H3-targeted CD28 bispecific antibody, costimulates T cells enhancing the anti-tumor activity of clinically active CD3 T cell engagers.Cancer Research · 2026
6. P0984Phase 1 Interim Results for XmAb942, a Potential Best-in-Class, Long-Acting Anti-TL1A Antibody for the Treatment of Inflammatory Bowel DiseaseJournal of Crohn s and Colitis · 2026
7. An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal FunctionClinical Pharmacology & Therapeutics · 2026
8. 17A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433)The Oncologist · 2025
9. Opportunities and Challenges of Hepatic Impairment Physiologically Based Pharmacokinetic Modeling in Drug Development—An IQ PerspectiveClinical Pharmacology & Therapeutics · 2025
10. IQ Survey Results on Current Industry Practices—Part 1: Immunogenicity Risk AssessmentClinical Pharmacology & Therapeutics · 2025
11. Phosphatidylserine (PS)-targeting chimeric Interferon (IFN) fusion proteins for anti-tumor applications2025
12. Peripherally administered TNF inhibitor is not protective against α-synuclein-induced dopaminergic neuronal death in ratsNeurobiology of Disease · 2025
13. An IQ Industry Perspective on Informing Dosing Recommendations in Patients With Renal ImpairmentClinical Pharmacology & Therapeutics · 2024
14. Peripherally administered TNF inhibitor is not protective against α-synuclein-induced dopaminergic neuronal death in rats2024
15. A B7-H3-targeted CD28 bispecific antibody enhances the activity of anti-PD1 and CD3 T-cell engager immunotherapiesMolecular Cancer Therapeutics · 2024
16. Translational PK/PD and the first-in-human dose selection of a PD1/IL15: an engineered recombinant targeted cytokine for cancer immunotherapyFrontiers in Pharmacology · 2024
17. Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White PaperClinical Pharmacology & Therapeutics · 2024
18. IL-15/IL-15Rα-Fc-Fusion Protein XmAb24306 Potentiates Activity of CD3 Bispecific Antibodies through Enhancing T-Cell ExpansionMolecular Cancer Therapeutics · 2024
19. Impact of COVID‐19 on the Conduct and Design of Clinical Trials: IQ Consortium PerspectiveClinical Pharmacology & Therapeutics · 2024
20. Abstract 6348: Unveiling diverse trimeric forms of STEAP1 in human prostate cancer cells: Exploring STEAP1-STEAP2 interdependence for expression and plasma membrane localizationCancer Research · 2024